Delivery Order SPE2DB25D9322-SPE2DB25FWAEV
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,547.40 by the Defense Logistics Agency (DLA) on September 12, 2025, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, with an ultimate completion date of October 3, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency (DLA) on September 4, 2025. The delivery order is for Xolair 150 mg/ml syringes, with an ultimate completion date of September 25, 2025. This award carries no set-aside designation, allowing the vendor to compete on equal footing in the federal procurement marketplace. The place of...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency for 150 mg/ml Xolair syringes valued at $1,547.40. This firm fixed-price delivery order, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, represents a specific pharmaceutical product requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA....
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $37,137.60 by the Defense Logistics Agency on September 23, 2025, for the supply of Xolair 150 mg/ml syringes. The contract employs firm fixed-price pricing with an ultimate completion date of October 15, 2025, and was awarded without set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $9,284.40 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on September 24, 2025, for XOLAIR 150 mg/ml syringes. The award, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 14, 2025, for the supply of Xolair 300 mg/2 mL syringes. The contract is valued at $3,720.96 and is structured as a firm fixed-price delivery order with an ultimate completion date of September 5, 2025. This award was made without a set-aside designation, allowing the vendor to compete on the open...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on October 14, 2025, for Xolair 150 mg/mL syringes, with a ceiling value of $6,189.60 and an ultimate completion date of November 4, 2025. This delivery order does not include a set-aside designation and represents a specific product request issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency's Medical Supply Chain for the supply of Xolair 150 mg/ml syringes. The award, issued on August 29, 2025, with an ultimate completion date of September 22, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $6,189.60 by the Defense Logistics Agency on October 22, 2025, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program...
- SPE2DB25D9322Indefinite Delivery Contract
- SPE2DB25D9322-SPE2DB25FWAEVDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 17, 2025, for Xolair 150 mg/mL syringes, with a ceiling value of $1,547.40. This firm fixed-price delivery order is part of DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at approximately $500 million and valid through November 2026. The award carries no set-aside designation, allowing the contractor to compete on a full and open basis despite its small business status. The ultimate completion date for this delivery order is October 8, 2025, with performance taking place at the contractor's facility in Park Ridge, Illinois. This delivery order supports the Defense Logistics Agency's mission to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. Xolair (omalizumab) is a monoclonal antibody treatment used in allergy and immunology applications. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its comprehensive IDC with the DLA to deliver branded and generic prescription drugs, biologics, and specialty medications directly to military health facilities. The contractor's consistent contract performance across an extensive portfolio of pharmaceutical products demonstrates its capability to meet federal procurement requirements for specialized medical treatments.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/17/25 |